A real-world observation on thrombopoietic agents for patients with cancer treatment-induced thrombocytopenia in China: A multicenter, cross-sectional study.
Mei-Ting ChenLu LiQing XiaXiaobing ChenZijun LiaoChang WangBo ShenMin ZhouQingyuan ZhangYanqiao ZhangLiting QianXianglin YuanZhehai WangCong XueXin AnBin LiuKangsheng GuMei HouXiaojia WangWei WangEnxiao LiJincai ZhongJing ChengYongqian ShuNong YangHuaqing WangRunxiang YangTianshu LiuTing DengFei MaWangjun LiaoWensheng QiuYu ChenXi ChenMingzhi ZhangRuilian XuXiaoling LiJifeng FengYi BaYanxia ShiPublished in: Cancer (2024)
To provide an overview of the outcome of cancer treatment-induced thrombocytopenia in China, our cross-sectional study analyzed 1437 cases treated with different thrombopoietic agents. Most of the patients were treated with recombinant interleukin 11 (rhIL-11) and recombinant thrombopoietin (rhTPO). rhTPO was associated with a significantly lower proportion of platelet recovery and platelet transfusion compared with rhIL-11.